FIRSTWORD PHARMA
Junevity debuts with $10M to turn back the clock on cellular damage
"My research at UCSF showed the power of targeting transcription factors to restore aged human cells back to health," said Sengstack, who helped found Junevity, and also serves as its chief scientific officer. "Based on these discoveries, we are bringing forward a new class of cell reset therapeutics for diseases, with the ultimate goal of greater human longevity."
RESET combs through billions of human disease data points — sourced from a combination of internally generated siRNA perturbation studies and public databases — and uses AI to rank and evaluate potential targets. The result is the Cell RESET Atlas, a list of transcription factors, organised by the cell types they're most active in, and the diseases that could benefit from targeting them.
